Clinical trials: Eye Cancer, Intraocular Melanoma
Unresectable Melanoma, Metastatic Cutaneous Melanoma
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells…
- Conditions
- Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
- Trial name
- DUET-MEL (NCT07627698)
- Testing
- EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Uveal Melanoma
5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes
Uveal Melanoma is a rare cancer with approximately 3,000 cases diagnosed in the US every year. Nearly half of these experience spread of their cancer outside the eye.
- Trial name
- CLEAR (NCT02376920)
- Volunteers
- 93 people
- Sponsor
- Castle Biosciences Incorporated
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Metastatic Uveal Melanoma
FHD-286 in Subjects With Metastatic Uveal Melanoma
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral…
- Trial name
- NCT04879017
- Testing
- FHD-286
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Foghorn Therapeutics Inc.
Uveal Melanoma
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma.
- Trial name
- NCT01430416
- Testing
- AEB071
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Uveal Melanoma, Ocular Melanoma
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT04417530
- Testing
- AU-011, Suprachoroidal Microinjector, PDT Laser
- Where
- 22 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aura Biosciences
Uveal Melanoma, Choroid Neoplasm
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal…
- Trial name
- NCT02771340
- Testing
- ICON-1
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Iconic Therapeutics, Inc.
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Cancer
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended…
- Trial name
- NCT04336241
- Testing
- RP2, nivolumab
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Replimune, Inc.
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Metastatic, Uveal Melanoma
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Selumetinib therapy in patients with metastatic uveal melanoma.
- Trial name
- SUMIT (NCT01974752)
- Testing
- 75mg selumetinib, Dacarbazine
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients…
- Conditions
- Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis
- Trial name
- NCT04328844
- Testing
- IOA-244, Avelumab Injection, Pemetrexed
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 210 people
- Sponsor
- iOnctura
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.